U.S., March 18 -- ClinicalTrials.gov registry received information related to the study (NCT07477431) titled 'Levetiracetam for Persons at Risk for Alzheimer's Disease' on Nov. 18, 2025.
Brief Summary: The goal of this clinical trial is to investigate whether very small doses of a drug called levetiracetam (LEV) may reduce abnormal brain signaling in individuals who are at an increased risk for developing Alzheimer's Disease (AD). The study is looking for individuals who have a parent or sibling with Alzheimer's disease (dementia), and who have memory complaints but are currently performing within normal limits on cognitive testing. During the screening period, a functional MRI (fMRI) scan of the brain will identify those participants who ...